Skip to main content
NurExone Biologic Inc logo

NurExone Biologic Inc — Investor Relations & Filings

Ticker · NRX ISIN · CA67059R1091 LEI · 25490047UWNZ2P8ESB77 TSXV Manufacturing
Open in API
Filings indexed 423 across all filing types
Latest filing 2025-02-19 Regulatory Filings
Country CA Canada
Listing TSXV NRX

About NurExone Biologic Inc

https://nurexone.com/

NurExone Biologic Inc. is a biopharmaceutical technology company specializing in the development of regenerative exosome-based therapies for Central Nervous System (CNS) injuries. The core of its business is the proprietary ExoTherapy platform, which utilizes nanosized extracellular vesicles (exosomes) as precision biological messengers and drug delivery vehicles. These exosomes are loaded with therapeutic compounds, creating nanodrugs designed to target inflamed or damaged neural tissue. A key product candidate is ExoPTEN, an siRNA sequence loaded onto exosomes, which has shown promise in regenerating and rewiring neurons in preclinical models of fully transected spinal cords. The company employs proprietary 2D and 3D production processes within its dedicated in-house bioreactor to ensure high-quality, large-scale production of potent exosomes.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing an annual contract renewal and partnership details. It is not a financial report, earnings release, management change, dividend notice, or other specific filing type. It represents a general corporate announcement and falls under the fallback category for miscellaneous regulatory announcements. Therefore, it should be classified as a Regulatory Filing (RNS).
2025-02-19 English
News release - English.pdf
Regulatory Filings
2025-02-14 English
News release - English.pdf
Regulatory Filings
2025-02-05 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 85% confidence The document is a Canadian securities regulator form (Form 45-106F1) reporting an exempt distribution of securities under NI 45-106. It is a SEDAR regulatory filing, not an earnings release, management discussion, or AGM material. It does not present financial results or serve as an annual/interim report, nor is it a press release. It is a miscellaneous regulatory filing to report a private placement, so it best fits the fallback category Regulatory Filings (RNS).
2025-01-31 English
Material change report - English.pdf
Capital/Financing Update Classification · 88% confidence 1. The document is titled “FORM 51-102F3 Material Change Report,” a Canadian securities filing describing a material change. 2. It details a non-brokered private placement (856,996 units for C$479,917.76) and the exercise of warrants (C$727,755.04 raised). 3. Both items are clear fundraising and capital-structure events (issuance of shares/warrants, proceeds raised). 4. Per the category definitions, “Capital/Financing Update (CAP)” covers updates on company fundraising, financing activities, or capital-structure changes. 5. Therefore, this filing best fits the CAP category.
2025-01-28 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a corporate press release detailing the closing of a non-brokered private placement, the exercise of warrants raising approximately C$1.2 million, and related financing terms. While it also announces the appointment of a new R&D Director, the core focus is on the company’s fundraising and capital-raising activities. This aligns with the definition of a Capital/Financing Update (CAP).
2025-01-21 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.